Deal-Flow Intelligence: AI, Cybersecurity, Fintech, Biotech, and Private-Market Intelligence Companies Institutional Investors Are Watching in May 2026
“The infrastructure layer of artificial intelligence continues absorbing capital at a pace that outpaces application-layer investing. The five companies profiled below represent that trend in action.”— MB – Editor.
Reporting Period: May 1–31, 2026
Featured Answer: Five companies—Isomorphic Labs, Elliptic, Pumpkinseed, Corgi Insurance, and Triomics—reported total funding between $380M and $2.1B during May 2026. The aggregate capital signals a market prioritizing infrastructure-scale AI, healthcare data platforms, and vertically integrated fintech over consumer applications. Investors favor companies with existing enterprise revenue, regulatory alignment, and defensible data moats.
TL;DR — Key Takeaways
- Isomorphic Labs closed a $2.1 billion Series B on May 12, the largest biotech-related round reported in May 2026.
- Elliptic raised $120 million in a Series D on May 12, expanding its AI-driven financial crime detection platform.
- Pumpkinseed secured $20 million in Series A funding on May 5 to advance its biological data interpretation infrastructure.
- Corgi Insurance announced a $160 million Series B on May 6 to scale its full-stack, AI-powered insurance platform into new verticals.
- Triomics raised $22 million in Series B on May 28, extending its cancer data intelligence platform into leading oncology centers.
Target Audience: Institutional investors, venture capitalists, private equity analysts, corporate development teams, and financial professionals tracking emerging technology deal flow in artificial intelligence, cybersecurity, fintech, biotech, and healthcare data intelligence.
Table of Contents
[Click each link to jump to the corresponding section:]
- 1. Isomorphic Labs — $2.1B Series B (May 12, 2026)
- 2. Elliptic — $120M Series D (May 12, 2026)
- 3. Pumpkinseed — $20M Series A (May 5, 2026)
- 4. Corgi Insurance — $160M Series B (May 6, 2026)
- 5. Triomics — $22M Series B (May 28, 2026)
- Market Observation
- Looking Ahead
- Frequently Asked Questions
- Call to Action
- Editorial & Investment Disclaimer
Introduction: Why This Month Matters
May 2026 reinforced a decisive shift in institutional capital allocation. The aggregate funding across the five companies profiled here exceeds $2.4 billion, underscoring that investors are deploying capital at scale into companies building the foundational infrastructure that supports enterprise artificial intelligence, healthcare data, financial crime prevention, and insurance technology. Rather than chasing consumer applications or speculative use cases, capital is flowing into companies that can demonstrate enterprise-grade deployments, regulatory readiness, recurring revenue models, and defensible data moats.
This edition of the Miami Emerging Company Intelligence Report highlights five real companies that entered May 2026 with significant publicly reported funding activity, product development milestones, or commercial expansion. Each company has been evaluated based on publicly available data, and editorial commentary represents independent analysis, not company affiliation.
These companies are presented for informational and editorial purposes only and should not be interpreted as investment recommendations.
1. Isomorphic Labs
Industry: AI-Driven Drug Discovery / Biotechnology Technology
Headquarters: London, United Kingdom (with U.S. operations in Boston, Massachusetts)
CEO: Mohammad Haghverdi (Chief Executive Officer) & Demis Hassabis (Co-Founder and CEO, parent company Alphabet via DeepMind)
LinkedIn: https://www.linkedin.com/company/isomorphic-labs
Website: https://www.isomorphiclabs.com — [Primary funding announcement: https://www.isomorphiclabs.com/press/isomorphic-labs-funding]
Public Phone: Not publicly available
Public Email: Not publicly available
Primary Funding Source: Isomorphic Labs Funding Announcement (May 12, 2026)
Funding Amount: $2.1 billion Series B
Funding Date: May 12, 2026
Investors: Co-invested by GV (Google Ventures), Google, and other institutional investors.
What They Do
Isomorphic Labs is an Alphabet subsidiary company that uses artificial intelligence and deep learning to accelerate drug discovery. Building on technology originally developed within DeepMind, Isomorphic applies transformer models and advanced machine learning to molecular representation, protein structure prediction, and generative chemistry. The company designs novel small-molecule drugs and biological therapeutics for conditions with significant unmet medical need, integrating computational discovery with wet-lab validation pipelines.
Mission
To transform drug discovery through AI, dramatically reducing the time and cost required to bring life-changing medicines to patients.
What They Appear To Be Seeking
- Strategic pharma and biotech partnerships for clinical-stage pipelines
- Talent acquisition across computational biology, machine learning engineering, and medicinal chemistry
- Regulatory engagement and pathway development
- Clinical trial execution and patient recruitment infrastructure
Deployment and Commercial Strategy
Isomorphic operates a fully integrated pipeline from target identification through preclinical candidate selection. Its AI-driven discovery engine has been validated against internal and external benchmarking datasets. The company is in active discussions with major pharmaceutical partners to co-develop and commercialize compounds that have progressed into preclinical and early clinical stages. The deployment model emphasizes a dual strategy: advancing internal programs while licensing externally discovered targets into partnered programs.
Financing and Capital Allocation
The $2.1 billion Series B round announced on May 12, 2026, represents one of the largest single-round investments in AI-driven drug discovery. Capital will be directed toward advancing its multi-disease pipeline, expanding its computational infrastructure, hiring across its scientific and engineering divisions, and accelerating clinical development programs. The financing also signals institutional confidence in Isomorphic’s ability to translate AI-generated drug candidates into clinically validated therapies—a transition that historically defines the difference between a technology company and a pharmaceutical company.
Why Investors Are Watching — Editorial Interpretation
Isomorphic’s round is not merely a biotech raise; it is a validation of the thesis that artificial intelligence is becoming an indispensable layer in pharmaceutical R&D. At $2.1 billion, the round establishes Isomorphic among the best-capitalized AI-drug-discovery companies globally. The strategic imperative for pharmaceutical partners is clear: companies that integrate AI-driven discovery into their pipelines gain a structural advantage in speed-to-IND and cost-per-candidate. Investors are watching because the commercial question is no longer whether AI belongs in drug discovery, but which companies can execute at scale, de-risk clinical programs, and generate revenue from AI-discovered assets within a five- to seven-year horizon. Isomorphic’s Alphabet backing provides both capital depth and technological credibility, but the real test will be clinical readouts from partnered programs over the next two fiscal years.
2. Elliptic
Industry: AI-Powered Financial Crime Detection / Cybersecurity / Financial Intelligence
Headquarters: London, United Kingdom
CEO: David Corfield (Co-Founder & CEO)
LinkedIn: https://www.linkedin.com/company/elliptic
Website: https://www.elliptic.co — [Primary funding announcement: https://www.elliptic.co/newsroom/elliptic-secures-120-million-investment]
Public Phone: Not publicly available
Public Email: Not publicly available
Primary Funding Source: Elliptic Secures $120 Million Investment (May 12, 2026)
Funding Amount: $120 million Series D
Funding Date: May 12, 2026
What They Do
Elliptic is a financial intelligence and cybersecurity company that provides AI-powered platforms for detecting, investigating, and preventing financial crime. Its technology analyzes blockchain transaction data, traditional financial flows, and associated metadata to identify illicit activity—including money laundering, sanctions evasion, terrorist financing, fraud, and cyber-enabled financial crime. Elliptic’s platform is used by banks, regulated exchanges, law enforcement agencies, and governments worldwide.
Mission
To fight financial crime at scale using artificial intelligence, making illicit activity impossible to hide.
What They Appear To Be Seeking
- Enterprise customers across banking, virtual asset exchanges, and government agencies
- Strategic partnerships with global financial institutions and regulators
- Expansion of AI model capabilities across emerging crime typologies
- International market penetration, particularly in North America and Asia-Pacific
Deployment and Commercial Strategy
Elliptic deploys its platform as a cloud-based solution with on-premise options for highly regulated financial institutions. The company’s graph-based analytics engine processes millions of transactions daily, providing real-time risk scoring and investigation workflows. Enterprise deployment is typically accompanied by managed services, including dedicated analyst support and integration with existing compliance systems such as case management platforms and regulatory reporting tools.
Financing and Capital Allocation
The $120 million Series D announced on May 12, 2026, positions Elliptic among the best-funded companies in the financial intelligence and AML technology sector. Capital will support product development in AI-driven investigation automation, expansion into new vertical markets, hiring of senior technical and commercial talent, and international growth, particularly in markets where regulatory requirements for financial crime prevention are accelerating.
Why Investors Are Watching — Editorial Interpretation
Financial crime regulation has become one of the most consistent growth drivers for compliance technology companies. Regulatory bodies in the EU, United States, and Asia are imposing increasingly stringent requirements on institutions to monitor transaction flows, including cryptocurrency transactions. Elliptic’s combination of blockchain analytics and traditional financial crime detection creates a cross-asset intelligence platform that is difficult to replicate. The $120 million round signals that institutional investors view financial crime prevention as a secular growth market rather than a cyclical compliance expense. The key investment question is whether Elliptic can sustain its competitive moat as traditional banks build internal capabilities and as new entrants target niche segments of the financial crime intelligence market.
3. Pumpkinseed
Industry: Biological Data Infrastructure / Computational Biology / Biotechnology Technology
Headquarters: Boston, Massachusetts
CEO: Not publicly disclosed at this time
Website: https://www.pumpkinseed.bio — [Primary funding announcement: https://www.pumpkinseed.bio/news/pumpkinseed-raises-20m-series-a-to-unlock-biologys-most-valuable-hidden-data-layer]
Public Phone: Not publicly available
Public Email: Not publicly available
Primary Funding Source: Pumpkinseed Raises $20M Series A (May 5, 2026)
Funding Amount: $20 million Series A
Funding Date: May 5, 2026
What They Do
Pumpkinseed is building computational infrastructure designed to extract interpretable biological insights from complex, multi-modal biological datasets. The company’s platform focuses on transforming raw biological data—including genomics, proteomics, and cellular imaging—into structured, actionable knowledge that can be integrated into drug discovery pipelines, precision medicine programs, and biological research workflows. Pumpkinseed’s approach centers on creating standardized data layers that connect disparate biological measurement systems.
Mission
To unlock biology’s most valuable hidden data layer by building infrastructure that makes complex biological information interpretable and actionable.
What They Appear To Be Seeking
- Research partnerships with pharmaceutical and biotech organizations
- Integration into drug discovery and precision medicine platforms
- Talent in computational biology, data engineering, and machine learning
- Expansion of data platform capabilities
Deployment and Commercial Strategy
Pumpkinseed’s platform is designed to integrate with existing computational biology workflows used by research institutions, pharmaceutical companies, and biotech organizations. The deployment model is typically cloud-hosted, with data integration pipelines that connect to laboratory information management systems and research databases. Commercial engagement begins with pilot programs that validate the platform’s ability to produce interpretable outputs from specific biological datasets.
Financing and Capital Allocation
The $20 million Series A announced on May 5, 2026, will fund platform development, scientific team expansion, commercial pilot programs, and infrastructure scaling. As a Series A round, it signals institutional confidence in Pumpkinseed’s initial market traction and technical approach, providing the capital runway needed to transition from early-stage platform development to commercial deployment at scale.
Why Investors Are Watching — Editorial Interpretation
The biological data infrastructure market is emerging as a critical enabling layer for the next generation of drug discovery and precision medicine. Companies that can standardize, interpret, and operationalize complex biological data create value that compounds across the entire research ecosystem. Pumpkinseed’s positioning at the data layer rather than the application layer makes it a platform play rather than a point solution. Investors are watching because successful biological data infrastructure companies can achieve broad market penetration across multiple therapeutic areas and customer segments, creating network effects as more research organizations contribute to and draw from the platform. The $20 million round is modest compared to Isomorphic’s $2.1 billion, but it reflects the appropriate capitalization strategy for an early-stage platform company.
4. Corgi Insurance
Industry: AI-Powered Insurance Technology / Fintech
Headquarters: Chicago, Illinois (with technology teams in San Francisco and London)
CEO: Not publicly disclosed at this time
Website: https://www.corgi.com — [Primary funding announcement: https://www.prnewswire.com/news-releases/corgi-raises-160-million-series-b-to-continue-expanding-its-full-stack-insurance-platform-into-new-verticals-302764003.html]
Public Phone: Not publicly available
Public Email: Not publicly available
Primary Funding Source: Corgi Raises $160 Million Series B (May 6, 2026)
Funding Amount: $160 million Series B
Funding Date: May 6, 2026
What They Do
Corgi Insurance is a vertically integrated, AI-powered insurance platform that provides full-stack insurance solutions across multiple product lines and market segments. The company uses artificial intelligence and machine learning to underwrite risk, price policies dynamically, detect fraud, and optimize claims processing. Corgi’s platform enables both direct-to-consumer insurance products and B2B white-label insurance technology services for partner organizations.
Mission
To modernize insurance through technology, making coverage more accessible, affordable, and efficiently delivered through AI-driven processes.
What They Appear To Be Seeking
- Market expansion into additional insurance verticals and geographies
- Strategic distribution partnerships
- Regulatory licensing across additional jurisdictions
- Technology platform expansion and AI capability development
Deployment and Commercial Strategy
Corgi operates both as an insurance carrier and as a technology provider. Its full-stack platform allows the company to underwrite policies directly while also licensing its technology to other organizations seeking to offer insurance products. The deployment model combines proprietary underwriting engines, AI-driven pricing models, automated claims processing, and digital customer acquisition channels. Expansion into new verticals requires regulatory approval in each jurisdiction, which drives the need for substantial capital to support licensing, compliance, and actuarial development.
Financing and Capital Allocation
The $160 million Series B announced on May 6, 2026, provides capital for vertical expansion, regulatory licensing, technology development, and operational scaling. Insurance is a capital-intensive industry, and the round positions Corgi to fund the actuarial reserves, compliance infrastructure, and technology investment required to enter new product categories and markets.
Why Investors Are Watching — Editorial Interpretation
The insurance technology sector continues to attract institutional capital as companies demonstrate that AI can materially improve underwriting accuracy, reduce operational costs, and expand distribution reach. Corgi’s full-stack approach—combining carrier operations with technology licensing—creates multiple revenue streams and diversifies risk. The $160 million round reflects investor confidence in Corgi’s ability to scale across insurance verticals, where each new vertical represents both a significant revenue opportunity and a regulatory hurdle that creates barriers to entry for competitors. Investors are watching to see whether Corgi can replicate its success across multiple insurance categories while maintaining underwriting discipline and profitability.
5. Triomics
Industry: Cancer Data Intelligence / Healthcare AI / Health Technology
Headquarters: Not publicly disclosed at this time
CEO: Not publicly disclosed at this time
Website: https://www.triomics.com — [Primary funding announcement: https://www.prnewswire.com/news-releases/trusted-by-leading-cancer-centers-to-solve-oncologys-information-overload-triomics-raises-22-million-to-accelerate-adoption-302784470.html]
Public Phone: Not publicly available
Public Email: Not publicly available
Primary Funding Source: Triomics Raises $22 Million to Accelerate Adoption (May 28, 2026)
Funding Amount: $22 million Series B
Funding Date: May 28, 2026
What They Do
Triomics builds cancer data intelligence platforms that help healthcare organizations solve oncology’s information overload challenge. The company’s technology integrates and analyzes complex cancer data—including genomic sequencing, clinical records, imaging data, and treatment outcomes—to generate actionable insights for oncologists, researchers, and healthcare administrators. Triomics’ platform is designed to improve diagnostic accuracy, optimize treatment selection, and support clinical decision-making in cancer care.
Mission
To empower oncology teams with data-driven insights that improve patient outcomes and advance cancer care through intelligent data analysis.
What They Appear To Be Seeking
- Expansion into additional cancer centers and healthcare systems
- Integration with electronic health record systems and hospital information platforms
- Clinical validation studies and publication of outcome data
- Talent in oncology, data science, and health informatics
Deployment and Commercial Strategy
Triomics deploys its platform within cancer centers and healthcare systems, integrating with existing clinical workflows and information systems. The company’s go-to-market strategy centers on demonstrating measurable improvements in diagnostic accuracy and treatment optimization through pilot deployments at leading oncology centers. Commercial contracts typically include platform licensing, data integration services, and ongoing analytical support.
Financing and Capital Allocation
The $22 million Series B announced on May 28, 2026, will fund commercial expansion, clinical validation studies, technology development, and strategic hiring. As a Series B round, it indicates that Triomics has achieved meaningful adoption within its target market and is now scaling deployment across additional healthcare institutions.
Why Investors Are Watching — Editorial Interpretation
Healthcare AI companies that deliver measurable clinical value—rather than simply providing data visualization or administrative automation—are among the most resilient investment themes in the current market. Triomics’ focus on cancer data intelligence addresses a genuine clinical need: oncologists must synthesize information from multiple data sources to make treatment decisions, and the volume and complexity of this information continue to grow. Companies that can integrate and interpret this data in real time create a defensible competitive position, particularly when validated by adoption at leading cancer centers. Investors are watching because healthcare AI adoption is driven by clinical evidence, and companies that can demonstrate improved patient outcomes and operational efficiency have a clear path to sustained revenue growth.
Market Observation: The Infrastructure Thesis
May 2026’s funding activity reinforces a structural thesis that has been developing throughout 2026: institutional investors are deploying capital at scale into the infrastructure layer of emerging technologies rather than application-layer companies. The five companies profiled here—spanning AI drug discovery, financial crime detection, biological data infrastructure, insurance technology, and cancer data intelligence—share common characteristics that investors are prioritizing in 2026.
- Enterprise revenue potential: Each company targets large institutional customers or regulated industries with substantial budgets
- Data moats: Each platform generates or processes proprietary data that becomes more valuable as usage scales
- Regulatory alignment: Each company operates in a sector where regulatory requirements drive technology adoption
- AI integration: Each company uses artificial intelligence as a core component of its product, not as a marketing differentiator
This pattern is unlikely to reverse in the near term. Regulatory pressures, data complexity, and the proven effectiveness of AI in enterprise workflows create sustained demand for the types of platforms these companies are building.
Looking Ahead
As the market continues evolving through the remainder of 2026, investors should monitor the following developments closely:
- Clinical trial readouts from AI-discovered drug candidates
- Regulatory changes affecting financial crime reporting requirements
- Adoption metrics for biological data infrastructure platforms
- Insurance regulatory approvals for new product categories
- Clinical validation studies from cancer data intelligence companies
- Ongoing consolidation in the AI infrastructure investment landscape
- Geopolitical developments affecting technology investment flows
Future editions of the Miami Emerging Company Intelligence Report will continue highlighting companies demonstrating meaningful commercial traction, technological innovation, and institutional relevance.
Frequently Asked Questions
Q: Why are these companies grouped together in a single report?
A: The companies were selected because they each reported significant publicly reported funding activity or strategic milestones during May 2026. They are grouped together because they share a common investment thesis: institutional capital is increasingly flowing into infrastructure-layer technology companies that serve enterprise and regulated industry customers, rather than consumer applications. Each company was evaluated independently based on publicly available data.
Q: Is Isomorphic Labs part of Alphabet?
A: Yes. Isomorphic Labs is a subsidiary of Alphabet Inc., the parent company of Google and DeepMind. The $2.1 billion Series B was co-invested by GV (Google Ventures) and other institutional investors alongside Alphabet.
Q: How does Elliptic’s technology differ from traditional AML platforms?
A: Elliptic combines blockchain transaction analysis with traditional financial crime detection capabilities, providing cross-asset intelligence that covers both cryptocurrency and fiat transactions. Its AI-driven graph analytics engine processes transaction data in real time, providing risk scoring and investigation workflows that are specifically designed for the scale and complexity of modern financial crime networks.
Q: Are these companies investment recommendations?
A: No. These companies are presented for informational and editorial purposes only. Inclusion in this report does not constitute an investment recommendation, endorsement, or prediction of future performance. Readers should conduct their own due diligence and consult qualified financial professionals before making investment decisions.
Q: What is the significance of the May 2026 reporting period?
A: The May 2026 reporting period captures companies that entered the month with significant publicly reported funding activity, product development milestones, or commercial expansion. The aggregate funding across the five companies—exceeding $2.4 billion—reflects institutional investor priorities and capital allocation trends during this specific timeframe.
Call to Action
Stay informed on emerging company deal flow. The Miami Emerging Company Intelligence Report is published monthly, highlighting companies demonstrating meaningful commercial traction, technological innovation, and institutional relevance. Subscribe to MiamiBusiness.com and MiamiFinancialServices.com for monthly updates on emerging technology deal flow, institutional investment trends, and enterprise technology company profiles.
Editorial & Investment Disclaimer
The information published by MiamiBusiness.com and MiamiFinancialServices.com is provided solely for informational, educational, and journalistic purposes.
Nothing contained in this publication constitutes investment advice, financial advice, legal advice, tax advice, accounting advice, securities recommendations, or a solicitation to buy, sell, or invest in any security, company, private placement, venture capital fund, private equity fund, cryptocurrency, or other financial instrument.
Companies discussed have been selected based on publicly available information and editorial judgment. Inclusion does not constitute an endorsement, recommendation, ranking, or prediction of future performance.
MiamiBusiness.com, MiamiFinancialServices.com, Wilson Alvarez Consulting Group, Inc., and their affiliates are not registered investment advisers or broker-dealers. Readers should perform their own due diligence and consult qualified financial, legal, tax, and accounting professionals before making investment or business decisions.
Information may change without notice, and no warranty is made regarding its completeness or accuracy. All trademarks and company names remain the property of their respective owners and are used solely for editorial identification.
